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We have recently identified a novel peptide in the rabbit prostate complex which cross-reacts with an antibody to thyro- 
trophin-releasing hormone (TRH) and has the structure pGlu-Glu-ProNH,. In the present study, high concentrations 
of a TRH-related tripeptide and also a polypeptide (l&l2 kDa) containing a TRH-immunoreactive peptide at its C-ter- 
minus were detected in human semen. The low molecular mass TRH-like peptide and the immunoreactive fragment from 
the polypeptide were isolated from human Semen and shown to have identical structum. Amino acid analysis suggested 
compositions Gl%, Pro,, and after mild acid hydrolysis, the same sequence, Glu-Glu-Pro, was established for the two 
peptides. Fast atom bombardment (FAB) mass spectrometry ielded a pseudomolecular ion (M + H)+ of 355.38 which 
was identical to that of the synthetic peptide pGlu-Glu-ProN&. The data demonstrate that human semen contains the 
TRH-like peptide pyroglutamylglutamylprolinamide and also a polypeptide terminating in the sequence Gln-Glu- 
ProNH,. 
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1. INTRODUCTION 
Rat prostate [1,2] and human semen [3,4] have 
been reported to contain high levels of im- 
munoreactive thyrotrophin-releasing hormone 
(TRH). We have recently detected a TRH-like 
tripeptide and a polypeptide containing a TRH im- 
munoreactive fragment at its C-terminus in the 
rabbit prostate complex and semen [5]. These TRH 
immunoreactive peptides did not correspond with 
authentic TRH, and after purification the low 
molecular mass peptide was identified as 
pyroglutamylglutamylprolinamide by amino acid 
analysis, N-terminal sequence analysis after mild 
acid hydrolysis, and fast atom bombardment 
(FAB) mass spectrometry [6]. This peptide differs 
from TRH by the substitution of glutamic acid for 
histidine at position 2. 
We report here that human semen contains the 
same TRH-related peptide pGlu-Glu-ProNH2 
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although it could not be detected in bull or ram 
semen. 
2. EXPERIMENTAL 
2.1. Semen collection 
Whole ejaculates were collected by 5 normal men aged be- 
tween 28 and 37 years. After ejaculation each volunteer im- 
mediately mixed the semen with 10 ml acidified acetone 
(acetone/HCl/HsO, 40: 1: 5) which was stored on ice for up to 
16 h before analysis. 
Bulls from an artificial insemination centre (Milk Marketing 
Board Freezing Unit, Little Horwood), which were accustomed 
to regular semen collection, were used as semen donors. Semen 
was collected using an artificial vagina from pre-stimulated 
(‘teased’) bulls [7], although on one occasion two sequential 
ejaculates were obtained from an unteased bull. Rams of mixed 
breed, which had been bred and kept at the National Institute 
for Medical Research, were trained to ejaculate into an artificial 
vagkna when presented with a teaser ewe [7]. After ejaculation, 
bulland ram semen (pooled ejaculates from 2 animals) was im- 
mediately mixed with 15 ml acidified acetone and stored on ice 
for a maximum of 4 h. 
2.2. Peptide synthesis 
The tripeptide pGlu-Glu-ProNHz and the C-terminally ex- 
tended TRH-related peptide (43 residues) from the rat prohor- 
mone: pGlu-His-Pro-Gly-Arg-Arg-Ala-Asn-Gln-Asp-Lys-Tyr- 
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Ser-Trp-Ala-Asp-Glu-Glu-Asp-Ser-Asp-Trp-Met-Pro-Arg-Ser- 
Trp-Leu-Pro-Asp-Phe-Phe-Leu-Asp-Ser-Trp-Phe-Ser-Asp-Val- 
Pro-Gln-Val, were synthesised by conventional fluorenyl- 
methoxycarbonyl methodology as described [5,6]. 
accelerating voltage of 8 keV using a 35 keV caesium ion gun 
[121. 
3. RESULTS AND DISCUSSION 
2.3. Detection of TRH-related peptides in semen 
The semen mixed with acidified acetone was centrifuged and 
the supernatant dried in vacua before dissolving in 25% acetic 
acid [5]. Peptides in the semen were resolved by gel-exclusion 
chromatography on Sephadex G-50 superfine (1 x 100 cm) in 
25% acetic acid. Aliquots of each fraction were dried in vacua 
and immunoreactive TRH was detected by radioimmunoassay 
(RIA) as in [8]. The TRH-related polypeptide in human semen 
was detected by RIA with the TRH antibody after excision of 
the immunoreactive fragment with trypsin [(20rg enzyme in 
50 ~1 of 0.05 M sodium phosphate (pH 8.2), 37”C, 6 h] follow- 
ed by cyclisation of the N-terminal glutamine (50% acetic acid, 
lOO”C, 20 min). 
The molecular mass of the TRH-related polypeptide was 
estimated by gel-exclusion chromatography on Sephadex G-100 
(1 x 100 cm) in 25% acetic acid. Aprotinin (6.5 kDa), “‘I- 
labelled rat &lipotrophin (9.9 kDa) and cytochrome c 
(12.4 kDa) were used to calibrate the column. 
2.4. Purification of the TRH immunoreactive peptides from 
human semen 
The peptides from a total of 17 ejaculates were separated by 
gel-exclusion chromatography as described above. A maximum 
of 4 ejaculates were analysed at one time and the fractions were 
frozen until all samples had been processed. Fractions contain- 
ing the TRH-related polypeptide were dried in vacua, the im- 
munoreactive fragment being excised by trypsin digestion and 
the N-terminal glutamine cyclised as described above. The im- 
munoreactive fragment thus generated and the low molecular 
mass TRH-related peptide were purified by ion-exchange 
chromatography and high-performance liquid chromatography 
(HPLC) as detailed elsewhere [6]. 
The TRH-related peptides present in extracts of 
human semen are illustrated in fig.1. Before en- 
zymic digestion, RIA with the TRH antibody 
revealed only the presence of low molecular mass 
TRH immunoreactivity in human semen 
(13.2 pmol immunoreactive peptide/ejaculate). 
After treatment with trypsin a high concentration 
of a TRH-related polypeptide (31.3 pmol im- 
munoreactive peptide/ejaculate) with a molecular 
mass of approx. lo-12 kDa was detected. This 
polypeptide must terminate with a TRH im- 
munoreactive fragment because one of the re- 
quirements for recognition by the TRH antibody is 
a C-terminal prolinamide which can only occur at 
the end of a peptide. The pattern of TRH-like pep- 
tides in human semen is remarkably similar to 
those in rabbit prostate complex and semen. In 
rabbit, high concentrations of a polypeptide 
(5-6 kDa) containing a TRH-like peptide at its C- 
terminus were observed in addition to low 
molecular mass TRH immunoreactivity [5,6]. 
2.5. Amino acid analysis 
In contrast to rabbit and human, TRH im- 
munoreactivity could not be detected in untreated 
fractions after gel-exclusion chromatography of 
extracts of bull and ram semen. This pronounced 
species difference in the distribution of TRH- 
related peptides is difficult to explain. The peptides 
Peptides were hydrolysed for 20 h at 110°C in 6 M HCI, 
2 mM phenol in the vapour phase under Nz. Analysis was per- 
formed using an Applied Biosystems 420A derivatiser-analyser 
fitted with an on-line 130A PTC-HPLC detection 191. 
2.6. Automated sequence analysis 
The peptides were incubated with 3 M HCI for 10 min at 
100°C in order to achieve partial conversion of the N-terminal 
pyroglutamic acid to glutamic acid [lo]. Sequence analysis was 
performed using Applied Biosystems 470A gas-phase and 477A 
pulsed liquid-phase peptide sequencers [ 1 I]. 
40 so 60 70 80 90 
2.7. Mass spectrometry Fraction 
The endogenous peptides were further purified and concen- 
trated to final volumes of 50~1 by microbore reverse-phase 
HPLC on an Applied Biosystems microsyringe pumping system 
[6]. For FAB mass spectrometry the peptides were dried to 
1.5 ~1 on the probe and mixed with 1 ,ul thioglycerol matrix con- 
taining 1% trifluoroacetic acid. Spectra were recorded by nor- 
mal scanning (310-1200, scan time = 0.05 decade) in the 
positive ion mode on a VG 70-250 SE mass spectrometer at an 
Fig.1. TRH-related peptides in human semen. Peptides 
extracted from 2 pooled semen samples (2 individuals) were 
resolved by gel-exclusion chromatography (Sephadex G-50 
superfine). Iodinated TRH (3 residues) and TRH-related 
peptide (43 residues) were used as molecular markers. Aliquots 
of each fraction were assayed for TRH after enzymic digestion 
as described in section 2. 
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may be present in the semen of bull and ram but 
at concentrations too low to be detected by our 
radioimmunoassay. Another explanation could be 
that the peptides occur in a fraction of the 
ejaculate that is not collected effectively by the 
standard protocol (see section 2). In this context, 
bulls are generally pre-stimulated or teased before 
collection of semen [7] and the fluid, which con- 
tains secretions from the accessory reproductive 
glands, is discarded because it does not contain 
viable sperm. For this reason, an ejaculate was col- 
lected from a bull which had not been pre- 
stimulated; nevertheless, TRH immunoreactivity 
was not detected in extracts of this ejaculate. 
In human, both the low molecular mass peptide 
and the immunoreactive fragment cleaved from 
the polypeptide exhibited identical chroma- 
tographic properties to the rabbit peptide: the pep- 
tides were retained on an anion exchanger (QAE- 
Sephadex) at pH 7.6 but not on a cation exchanger 
(SP-Sephadex) at pH 2.0. Unexpectedly, the im- 
munoreactive fragment from the polypeptide in 
rabbit prostate and semen was not retained on the 
cation and anion exchangers or on a reverse-phase 
HPLC column. 
The TRH-related peptides were purified from 
human semen by anion-exchange chromatography 
and reverse-phase HPLC yielding, as estimated by 
amino acid analysis, approx. 0.5 nmol low 
molecular mass peptide and 1.0 nmol tryptic frag- 
ment. In order to conserve the peptides for mass 
spectrometry, less than 20 pmol of each were sub- 
jected to amino acid analysis. The recoveries of 
both aspartic and glutamic acids are often poor 
when strong acid hydrolysis is carried out at these 
low levels. For this reason, a similar concentration 
of the synthetic peptide pGlu-Glu-ProNHz was 
hydrolysed under the same conditions as the 
purified peptides in order to give an internal 
estimate for the recovery of glutamic acid (50%). 
Both peptides, after correction for loss of glutamic 
acid, gave an approximate ratio of Glx : Pro of 2 : 1 
by amino acid analysis: low levels of the ubi- 
quitous amino acids serine and glycine were also 
present. Both of the purified peptides appeared to 
cross-react 50% with the TRH antibody as do the 
synthetic peptide pGlu-Glu-ProNHz and the en- 
dogenous peptide from rabbit prostate [6]. 
The purified peptides were resistant to Edman 
degradation but after mild acid hydrolysis to con- 
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Fig.2. Sequence analysis of the purified TRH-related peptides 
from human semen. Automated sequencing on 100 pmol 
synthetic pGlu-Glu-ProNHz (o), 100 pmol purified TRH- 
immunoreactive fragment from the 10 kDa polypeptide from 
human semen (+) and 60 pmol low molecular mass TRH-like 
peptide in human semen (m). Results are normalised with 
respect o the yield on the first cycle of Edman degradation for 
ease of comparison. 
vert partially the N-terminal pyroglutamic acid to 
glutamic acid [lo], sequence analysis of the low 
molecular mass TRH-like peptide and the im- 
munoreactive fragment from the polypeptide 
demonstrated the sequence Glu-Glu-Pro (fig.2). 
The yields of the amino acids in each of the three 
cycles of Edman degradation were similar to those 
of the synthetic peptide pGlu-Glu-ProNHz. It is in- 
teresting that proline was observed in the second 
round of Edman degradation of the low molecular 
mass peptide from rabbit prostate [6] which we 
had previously suggested may be ‘due to slight 
cleavage of the Glu-Glu peptide bond during the 
opening of the pyroglutamyl ring’. In the present 
study, although both of the purified peptides and 
the synthetic peptide were subjected to mild acid 
hydrolysis under identical conditions, proline was 
observed in the second round of Edman degrada- 
tion of only the low molecular mass TRH-like pep- 
tide. An alternative explanation of these results is 
that the low molecular mass peptides purified from 
both rabbit prostate and human semen contain a 
minor dipeptide contaminant. Glu-Pro diketo- 
piperazine would not react with the TRH antibody 
used in this study but may have similar 
chromatographic properties on the ion exchangers 
used for purification. The diketopiperazine lutes 
slightly after pGlu-Glu-ProNH2 during reverse- 
phase HPLC and incomplete separation of the two 
peptides may lead to a minor contamination with 
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the dipeptide. The conditions of mild acid Synthetic pGlu-Glu-ProNHz and purified pep- 
hydrolysis used for sample treatment before gas- tides were subjected to FAB mass spectrometry 
phase sequencing may be sufficient to open the and the spectra, generated on the same day and us- 
ring structure of the diketopiperazine to reveal a ing the same calibration file, are illustrated in 
free N-terminus for Edman degradation. fig.3. A clear pseudomol‘ecular ion, (M +H)+ = 
A. Synthetic pGlu-Glu-ProNH2 
B. Semen peptide 
C. Blank 
100 
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Fig.3. Structural analysis of TRH-related peptide in human semen by FAB mass spectrometry. The spectra illustrated are taken at 
the same time interval after introduction of the sample into the FAB source (scan 13). (A) 700 pmol synthetic peptide pGlu-Glu- 
ProNHs, (B) 700 pmol purified TRH-immunoreactive fragment from the lo-12 kDa polypeptide and (C) HPLC buffer (blank). 
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355.38, was observed in the positive ion mode for 
the endogenous peptide which was identical to that 
for the synthetic peptide, 355.38. Additional peaks 
in the spectra represented matrix or buffer com- 
ponents (329, 331, 361, 455) and were present in 
the buffer blank with the exception of the ion at 
377 which represented the sodium adduct of the 
peptide, (M + Na)+ = 354 + 23. These results con- 
firmed the structure of the purified peptide from 
human semen as pGlu-Glu-ProNHz. 
In conclusion, it is clear that the TRH-like 
tripeptide in human semen is pyroglutamylgluta- 
mylprolinamide. This peptide occurs naturally in 
the semen but can also be generated in vitro after 
tryptic cleavage of a polypeptide (lo-12 kDa) and 
incubation under conditions which facilitate 
cyclisation of N-terminal glutamine. Thus, the 
polypeptide must terminate in the sequence Gln- 
Glu-ProNHz. As the tripeptide is released by tryp- 
sin, the TRH-like sequence must be immediately 
preceded by at least one basic amino acid residue. 
It is likely that the new tripeptide is formed from 
the polypeptide in vivo by proteolytic processing at 
this site [ 131 followed by N-terminal cyclisation of 
the exposed glutaminyl residue by glutaminyl 
cyclase [14,15]. 
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